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This collection of 10 articles in Frontiers and Cellular Microbiology
aims to present the current opportunities for development of
innovative therapeutic strategies for tularemia, a zoonotic disease
caused by Francisella tularensis. This Gram-negative, facultative
intracellular bacterium is a class 3 human pathogen and a CDC
category A bioterrorism agent. Two F. tularensis subspecies are
responsible for tularemia in humans, subsp. holarctica (type B) in
the northern hemisphere and subsp. tularensis (type A) in North
America, which themselves are split into genotypes of variable
virulence. F. tularensis is transmitted to humans via the dermal,
oral, conjunctival or respiratory routes, through direct contact
with infected animals (specifically lagomorphs), ingestion of con-
taminated food or water, inhalation of contaminated aerosols,
or arthropod bites (mainly ticks). The disease usually manifests
as a regional lymphadenopathy (ulceroglandular, glandular, ocu-
loglandular, and pharyngeal forms), or as systemic typhoid-like
(typhoidal form) or pneumonic (pneumonic form) diseases. This
latter form is themost feared in the context of bioterrorism. There
is no vaccine for tularemia, and few antibiotics are effective in
treating tularemia patients, including the aminoglycosides (strep-
tomycin and gentamicin), the fluoroquinolones and the tetracy-
clines. No acquired resistance to these drugs has been reported
in clinical situations, but antibiotics resistant strains could be
genetically engineered for biothreat purposes. Thus, tularemia
is a relevant model for development of modern anti-infective
alternatives.
Because tularemia is a rare disease, clinical trials in infected
humans for comparing different therapeutic strategies are not
feasible. A number of in vitro and in vivo models have been devel-
oped for evaluation of new treatment alternatives. Importantly,
the most relevant models are those using the highly virulent A1b
genotype strains of F. tularensis, especially the Schu S4 strain.
However, experiments using this select agent must be performed
in biological safety level 3 laboratories and are submitted to dras-
tic regulation in most countries. Thus, F. tularensis strains with
attenuated virulence have been used for decades in research labo-
ratories, especially the F. novicida Utah 112 strain. In a compara-
tive review, Kingry and Petersen (2014) clearly demonstrate that
F. novicida should no longer be used as a surrogate of F. tularen-
sis for therapeutic efficacy testing in animal models. These two
bacteria strongly differ in their natural life cycle, behavior in
phagocytes, immunomodulatory properties, and pathogenicity to
humans.
Potential new therapeutic strategies for tularemia include the
development of new antibiotics or new ways of using exist-
ing antibiotics, the reduction of F. tularensis virulence and
the enhancement of the host innate and/or adaptive immune
response (Boisset et al., 2014). Hamblin et al. (2014) report here
the high in vivo efficacy of a commercial formulation of liposome-
encapsulated ciprofloxacin (Lipoquin®, AradigmCorporation) in
mice challenged with the Schu S4 strain. While developing a new
dye uptake assay to test the activity of antibiotics against intracel-
lular F. tularensis, Sutera et al. (2014) found a significant activity
of linezolid (whose activity is currently restricted to Gram-
positive bacteria) against intracellular F. tularensis. Schmitt et al.
(2013) report the intracellular bactericidal activity of resazurin,
a compound used for a long time to evaluate the bacterial and
eukaryotic cell viability, against F. tularensis and Neisseria gonor-
rhoeae (gonorrhea agent). Caspar et al. (2014) present the activity
of novel synthetic bis-indole derivatives against F. tularensis,
although their cytotoxicity precluded evaluation of their activity
against the intracellular form of the bacterium.
Opportunities to develop anti-infective agents inhibiting
F. tularensis virulence or modulating the immune host response
are then discussed. Jones et al. (2014) summarize the mecha-
nisms of virulence of F. tularensis, including: (1) a capsule-related
resistance of F. tularensis to opsonization and killing by the
complement; (2) lack of activation of TLR4 cytokine response
pathway by the lipid A of F. tularensis LPS leading to a poor
inflammatory response of the phagocytic cells; (3) F. tularensis
escape of phagolysosomal pathway of phagocytic cells thanks to
effectors encoded by a number of genes gathered in the Francisella
pathogenicity island (FPI); (4) alteration of several adaptive
immune response pathways precluding development of an effi-
cient host response. The intracellular multiplication of F. tularen-
sis may first be altered by blocking nutrient retrieval of this bac-
terium within its eukaryotic host cell. As an example, Abu Kwaik
(2013) report that, to increase intracellular cysteine concentra-
tion, F. tularensis cleaves intracellular host glutathione using a
gamma-glutamyl transpeptidase, an enzyme that could repre-
sent a useful therapeutic target. F. tularensis is able to infect and
multiply in polymorphonuclears (PMN), a rare property among
pathogenic bacteria. Allen (2013) describes how F. tularensis turns
the intrinsic properties of the PMNs to increase its pathogenicity,
including PMNs longevity enhancing due to apoptosis block-
ade, accumulation of PMNs in infected tissues, granuloma
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formation and finally extensive tissue damages. Gillette et al.
(2014) summarize how F. tularensis perturbs the host immune
response by altering the intracellular signaling pathways of mono-
cytes/macrophages. Each step of F. tularensis-induced dysreg-
ulation of the inflammatory process may represent a target
for development of molecules capable of restoring the host
immune response. Gillette et al. (2014) mention the poten-
tial clinical usefulness of available immunomodulatory com-
pounds for treatment of severely diseased tularemia patients,
including type I and type II interferons, celecoxib, imiquimod,
and the granulocyte-macrophage colony-stimulating factor
(GM-CSF).
In conclusion, promising opportunities exist to improve the
treatment of severe forms of tularemia. However, it is probable
that none of them taken separately may solve all clinical situ-
ations. The combination of one or several immunomodulatory
strategies with the administration of drugs inhibiting growth
and/or virulence of F. tularensis may represent new and interest-
ing therapeutic alternatives, which justifies having simultaneously
addressed these different aspects in the present research topic.
As an editor of this research topic, I would like to greatly thank
all coauthors for their valuable and interesting contributions.
We wish the readers of this e-book a productive and enjoy-
able reading, and we hope that new ideas will emerge on this
topic.
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